Nuvation Bio Inc. · NYSE:NUVB

Nuvation Bio — Investor Presentation (October 2024)

40 slides from Nuvation Bio's investor presentation, October 2024

  1. Slide 1: Driven by Science, Focused on Life

    Slide 1: Driven by Science, Focused on Life

    DRIVEN BY SCIENCE FOCUSED ON LIFE October 2024

  2. Slide 2: Forward looking statements

    Slide 2: Forward looking statements

    Forward looking statements Certain statements included in this presentation (this “Presentation”) that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statemen

  3. Slide 3: Nuvation Bio is tackling some of the greatest unmet needs in oncology

    Slide 3: Nuvation Bio is tackling some of the greatest unmet needs in oncology

    Nuvation Bio is tackling some of the greatest unmet needs in oncology Late clinical-stage, global oncology company with multiple candidates in development aimed at improving validated mechanisms that have encountered safety liabilities or limitations in efficacy Taletrectinib1 is a next-generation,

  4. Slide 4: Nuvation Bio is developing a broad pipeline of differentiated and novel therapeutic candidates

    Slide 4: Nuvation Bio is developing a broad pipeline of differentiated and novel therapeutic candidates

    Nuvation Bio is developing a broad pipeline of differentiated and novel therapeutic candidates Current Stage of Development Program Potential Indication(s) Anticipated Milestones & Recent Updates Preclinical Phase 1 Phase 2 Pivotal • Most mature and pooled data from pivotal TRUST-I & Taletrectinib1

  5. Slide 5: Taletrectinib | ROS1i

    Slide 5: Taletrectinib | ROS1i

    Taletrectinib | ROS1i Advanced ROS1- Planned NDA positive NSCLC submission in Q4 2024 5

  6. Slide 6: Taletrectinib is a next-generation, potentially best-in-class ROS1 inhibitor

    Slide 6: Taletrectinib is a next-generation, potentially best-in-class ROS1 inhibitor

    Taletrectinib is a next-generation, potentially best-in-class ROS1 inhibitor differentiated by response rate, duration, and tolerability Commercial opportunity Differentiated profile Strong partnerships • Planned NDA submission (line • Potentially best-in-class efficacy • In-licensed from Daiichi Sa

  7. Slide 7: The ROS1-positive NSCLC market represents a sizeable commercial opportunity

    Slide 7: The ROS1-positive NSCLC market represents a sizeable commercial opportunity

    The ROS1-positive NSCLC market represents a sizeable commercial opportunity Key takeaways Estimated diagnosed patient population • NSCLC accounts for ~80-85%1 of all lung cancers • ROS1-positive lung cancer represents ~2%2 of new NSCLC cases ~2,000-4,0001,2 ~1,000-2,0002,6 • There are currently thre

  8. Slide 8: Taletrectinib evaluated in two pivotal registrational studies, >300 patients

    Slide 8: Taletrectinib evaluated in two pivotal registrational studies, >300 patients

    Taletrectinib has been evaluated in two pivotal registrational studies that include >300 patients in total, with results supporting BTDs1 in U.S. & China TRUST-I TRUST-II Pivotal China Phase 2 Pivotal Global Phase 2 n=173 n=1535 Stage 1 Cohort 1 (n=55) Taletrectinib 400 mg QD2 ROS1-TKI naïve Dose se

  9. Slide 9: Pooled pivotal TRUST-I & TRUST-II data in advanced ROS1-positive NSCLC

    Slide 9: Pooled pivotal TRUST-I & TRUST-II data in advanced ROS1-positive NSCLC

    Pooled pivotal TRUST-I & TRUST-II data included 337 patients1 with advanced ROS1-positive NSCLC, 273 of which form the response evaluable population Key eligibility criteria Response evaluable population Endpoints • Locally advanced or metastatic NSCLC Primary: • Age ≥18 years2 ROS1 TKI-naïve (n=160

  10. Slide 10: Taletrectinib well-positioned against approved ROS1 TKIs in first line

    Slide 10: Taletrectinib well-positioned against approved ROS1 TKIs in first line

    Taletrectinib is well-positioned against approved ROS1 TKIs in the first line setting (TKI-naïve patients) based on both response rate and durability Taletrectinib2 Repotrectinib3 Entrectinib4 Crizotinib5 ALKA-372-001, Study Pooled TRUST-I & TRUST-II TRIDENT-1 STARTRK-1, STARTRK-2 PROFILE 1001 n 160

  11. Slide 11: Progression-free survival of taletrectinib exceeds XTANDI & TAGRISSO in metastatic disease

    Slide 11: Progression-free survival of taletrectinib exceeds XTANDI & TAGRISSO in metastatic disease

    Progression-free survival of taletrectinib exceeds XTANDI & TAGRISSO in metastatic disease Program Progression-free survival XTANDI (enzalutamide) • PREVAIL1: 20 months TAGRISSO (osimertinib) • FLAURA2: 19 months taletrectinib • Pooled TRUST-I & TRUST-II3: 46 months 11 Note: These data are derived f

  12. Slide 12: Taletrectinib response in TKI-pretreated patients compares favorably to other ROS1 TKIs

    Slide 12: Taletrectinib response in TKI-pretreated patients compares favorably to other ROS1 TKIs

    Taletrectinib’s response rate and duration in TKI-pretreated patients compares favorably to other ROS1 TKIs Taletrectinib2 Repotrectinib3 Zidesamtinib4 Study Pooled TRUST-I & TRUST-II TRIDENT-1 ARROS-1 Crizotinib & entrectinib Repotrectinib n 113 56 17 3 cORR 56% 38% 53% 0% Median DOR 17 months 15 m

  13. Slide 13: Taletrectinib shows encouraging safety profile relative to approved ROS1 TKIs

    Slide 13: Taletrectinib shows encouraging safety profile relative to approved ROS1 TKIs

    Taletrectinib data show an encouraging safety profile relative to approved ROS1 TKIs, including improved dose modification and low rates of neuro AEs Dose Modification Neurological AEs 80% 80% 65% 60% 60% 54% 50% 46% 44% 41% 40% 38% 40% 38% 29% 29% 26% 21% 20% 22% 19% 18% 20% 20% 15% 11% 12% 10% 9%

  14. Slide 14: Planned Q4 2024 NDA will enable U.S. launch of taletrectinib in 2025

    Slide 14: Planned Q4 2024 NDA will enable U.S. launch of taletrectinib in 2025

    Nuvation Bio’s planned NDA submission in Q4 2024 will, upon regulatory approval, enable a U.S. launch of taletrectinib in 2025 Upon regulatory approval, Nuvation Bio is positioned to commercialize a novel targeted therapy for patients with advanced ROS1-positive NSCLC in need of better treatment opt

  15. Slide 15: Safusidenib | mIDH1i

    Slide 15: Safusidenib | mIDH1i

    Safusidenib | mIDH1i Diffuse Phase 2 study ongoing IDH1-mutant glioma 15

  16. Slide 16: Safusidenib is a potentially best-in-class, brain penetrant, mIDH1 inhibitor

    Slide 16: Safusidenib is a potentially best-in-class, brain penetrant, mIDH1 inhibitor

    Safusidenib is a potentially best-in-class, brain penetrant, mIDH1 inhibitor in Phase 2 development for the treatment of patients with diffuse IDH1-mutant glioma Unmet need Validated target Differentiated profile Global rights • People diagnosed with • Vorasidenib1 approved to • Encouraging early da

  17. Slide 17: The diffuse IDH1-mutant glioma market represents a sizeable commercial opportunity

    Slide 17: The diffuse IDH1-mutant glioma market represents a sizeable commercial opportunity

    The diffuse IDH1-mutant glioma market represents a sizeable commercial opportunity Grade 3 ~13.3K – 18.3K ~37% people living with diffuse IDH1- Grade 2: mutant glioma in the U.S. ~63% Diffuse IDH1-mutant glioma patients are in need of better treatment options 17 Source: CBTRUS Statistical Report: U.

  18. Slide 18: Safusidenib clinical study data set approaches 100 patients

    Slide 18: Safusidenib clinical study data set approaches 100 patients

    Safusidenib clinical study data set approaches 100 patients Sponsor: Daiichi Sankyo Sponsor: Nuvation Bio J101 – Phase 1 G203 – Phase 2 Japan Global Grades 2-4 IDH1-mutant glioma Diffuse IDH1-mutant glioma n=47 Part 1: Dose evaluation (n=25) Part 2: Design under discussion J201 – Phase 2 Japan Grade

  19. Slide 19: Royalty Pharma's acquisition of vorasidenib royalty validates safusidenib's market potential

    Slide 19: Royalty Pharma's acquisition of vorasidenib royalty validates safusidenib's market potential

    Royalty Pharma’s acquisition of rights to Agios Pharmaceuticals’ royalty on U.S. net sales of vorasidenib validates safusidenib’s market potential Transaction highlights1 Implications to safusidenib • On May 28, 2024, Royalty Pharma announced it acquired an interest in Agios Pharmaceuticals’ royalty

  20. Slide 20: Safusidenib efficacy signals in enhancing and non-enhancing glioma relative to vorasidenib

    Slide 20: Safusidenib efficacy signals in enhancing and non-enhancing glioma relative to vorasidenib

    Safusidenib generated encouraging efficacy signals in IDH1-mutant enhancing and non-enhancing glioma relative to vorasidenib Safusidenib1 Vorasidenib2 Enhancing glioma n=35 Enhancing glioma n=30 Non-enhancing glioma n=12 Non-enhancing glioma n=22 40% 40% 33% 20% 17% 20% 18% 0% 0% 0% ORR ORR Enhancin

  21. Slide 21: NUV-1511 | DDC

    Slide 21: NUV-1511 | DDC

    NUV-1511 | DDC Advanced solid Phase 1/2 study ongoing tumors 21

  22. Slide 22: Drug-drug conjugate platform is a potential advance beyond ADCs

    Slide 22: Drug-drug conjugate platform is a potential advance beyond ADCs

    Nuvation Bio’s drug-drug conjugate (DDC) platform is a potentially revolutionary advance beyond ADCs Antibody-drug conjugates Drug-drug conjugates ✓ Improves therapeutic index vs. untargeted ✓ Tissue-selective targeting improves warhead therapeutic index vs. untargeted warhead  IV delivery ✓ Oral o

  23. Slide 23: DDCs are designed to bind two different targets simultaneously

    Slide 23: DDCs are designed to bind two different targets simultaneously

    DDCs are designed to bind TWO different targets simultaneously Two separate drugs with two separate targets Fuse Binding Domains Drug Target X Drug Target Y Drug X Drug Y Drug Target X Drug Target Y Drug X Drug Y 23

  24. Slide 24: NUV-1511 suppresses prostate and breast cancer growth in xenografts

    Slide 24: NUV-1511 suppresses prostate and breast cancer growth in xenografts

    NUV-1511, a DDC derivative of a widely used chemotherapy agent, suppresses prostate and breast cancer growth in xenografts Prostate cancer CDX (LNCAP) ER+ breast cancer CDX (T47D) 2500 1000 2000 750 Tumor Volume (mm3) Tumor Volume (mm3) 1500 500 1000 250 500 0 0 0 7 14 21 28 35 0 7 14 21 28 35 Day D

  25. Slide 25: Intermittent dosing of NUV-1511 leads to sustained tumor inhibition

    Slide 25: Intermittent dosing of NUV-1511 leads to sustained tumor inhibition

    Intermittent dosing of NUV-1511 leads to sustained tumor inhibition for weeks Prostate cancer CDX (LNCAP) 2000 1500 Tumor Volume (mm3) 1000 500 0 0 7 14 21 28 Day Vehicle Chemo dose regimen 1 Chemo dose regimen 2 NUV-1511 dose regimen 1 NUV-1511 dose regimen 2 25 CDX: Cell-line derived xenograft.

  26. Slide 26: NUV-1511 initially evaluated in five indications

    Slide 26: NUV-1511 initially evaluated in five indications

    NUV-1511 is initially being evaluated in five indications for which there is a significant unmet need or large market potential Nuvation Bio initiated a Phase 1/2 study evaluating NUV-1511 for the treatment of patients with: Advanced solid tumors who previously received and progressed on or after tr

  27. Slide 27: NUV-868 | BETi

    Slide 27: NUV-868 | BETi

    NUV-868 | BETi Advanced solid Completed Phase 1 tumors and Phase 1b studies Currently evaluating Future indications next steps for program 27

  28. Slide 28: First generation BET inhibitors have been toxic and poorly effective

    Slide 28: First generation BET inhibitors have been toxic and poorly effective

    First generation BET inhibitors have been toxic and poorly effective NUV-868 is the most selective BD2 vs BD1 BET inhibitor in development BRD4 Affinity2 • BET proteins regulate the expression of many BD2 BD1 Selectivity oncogenes, including cMYC – an oncogene (nM) (nM) that has not been targetable

  29. Slide 29: Committed team tackling the greatest unmet needs in oncology

    Slide 29: Committed team tackling the greatest unmet needs in oncology

    Committed team tackling the greatest unmet needs in oncology Experienced biotech leadership team Broad pipeline across multiple stages of • Founded by Dr. David Hung, previously the development founder and CEO of Medivation, who successfully • Taletrectinib | ROS1 inhibitor: developed and commercial

  30. Slide 30: Appendix

    Slide 30: Appendix

    Appendix spo ey Nuvation Bio SVE

  31. Slide 31: Taletrectinib (ROS1i)

    Slide 31: Taletrectinib (ROS1i)

    Taletrectinib (ROS1i) Summary of data from pooled TRUST-I & TRUST-II studies 31

  32. Slide 32: RECIST responses in 89% of TKI-naïve and 56% of TKI-pretreated patients

    Slide 32: RECIST responses in 89% of TKI-naïve and 56% of TKI-pretreated patients

    RECIST responses were observed in 89% of taletrectinib-treated patients who were TKI-naïve and 56% of those who were TKI-pretreated TKI-naïve (n=160)1 100 80 Best percentage change 60 in sum of diameters from baseline, % 40 20 cORR: 0 * 89% -20 -40 95% CI: 83, 93 -60 -80 cCR cPR SD PD -100 Brain met

  33. Slide 33: Median duration of response and PFS in TKI-naïve patients were 44 and 46 months

    Slide 33: Median duration of response and PFS in TKI-naïve patients were 44 and 46 months

    Median duration of response and median progression free survival in TKI-naïve patients were 44 and 46 months TKI-naïve (n=160) TKI-pretreated (n=113) Median follow-up: 21 months2 Median follow-up: 21 months2 1.0 mDOR1: 44 months 1.0 mDOR1: 17 months 70% (95% CI: 30, NR) (95% CI: 11, 27) 61% (Kaplan-

  34. Slide 34: Intracranial RECIST responses in 77% and 66% of patients

    Slide 34: Intracranial RECIST responses in 77% and 66% of patients

    Intracranial RECIST responses were observed in 77% and 66% of taletrectinib-treated patients who were TKI-naïve and TKI-pretreated TKI-naïve (n=17)1 100 80 Best percentage change 60 in sum of diameters from baseline, % 40 IC-cORR: 20 0 77% -20 95% CI: 50, 93 -40 -60 -80 cCR cPR SD PD -100 Prior chem

  35. Slide 35: RECIST responses consistent across multiple subgroups

    Slide 35: RECIST responses consistent across multiple subgroups

    RECIST responses were consistent across multiple subgroups of taletrectinib- treated patients who were TKI-naïve and TKI-pretreated TKI-naïve (n=160) TKI-pretreated (n=113) Overall cORR: 89% Overall cORR: 56% Region Brain mets Prior chemo Region Brain mets Prior chemo 100% 100% 90% 89% 89% 87% 88% 8

  36. Slide 36: Taletrectinib safety profile favorable with low incidence of neurologic TEAEs

    Slide 36: Taletrectinib safety profile favorable with low incidence of neurologic TEAEs

    Taletrectinib’s safety profile was favorable with low incidence of neurologic TEAEs; only 7% of patients had a TEAE leading to treatment discontinuation TEAE: n (%) Any grade Grade 1 Grade 2 Grade ≥31 Commentary Increased AST 243 (72) 161 (48) 56 (17) 26 (8) Increased ALT 229 (68) 135 (40) 60 (18) 3

  37. Slide 37: NUV-1511 (DDC)

    Slide 37: NUV-1511 (DDC)

    NUV-1511 (DDC) Phase 1 study protocol 37

  38. Slide 38: NUV-1511 Phase 1 study protocol explores two dosing schedules

    Slide 38: NUV-1511 Phase 1 study protocol explores two dosing schedules

    NUV-1511 Phase 1 study protocol provides flexibility to explore two dosing schedules while efficiently determining a RP2D Modified i3 + 3 design Dose Level 1 Dose Level 2 Dose Level 3 Dose Level 4 Continue until Dosing 3-6 patients 3-6 patients 6-12 patients 6-12 patients MTD or RP2D Schedule A Back

  39. Slide 39: NUV-868 (BETi)

    Slide 39: NUV-868 (BETi)

    NUV-868 (BETi) BD2 inhibition 39

  40. Slide 40: BD2 selectivity blocks resistance pathways and increases tolerability

    Slide 40: BD2 selectivity blocks resistance pathways and increases tolerability

    BD2 selectivity blocks the ability of cancer cells to induce resistance pathways and, by avoiding BD1 inhibition, increases tolerability BD1 inhibition BD2 inhibition • Regulates steady state gene expression • Regulates rapid gene induction • Displaces BET proteins already associated with histones •

Source: Internet Archive copy of s27.q4cdn.com

More decks from Nuvation Bio Inc.

All 20 Nuvation Bio decks